Patents Assigned to Asahi Kasei Pharma Corporation
-
Publication number: 20210077590Abstract: [Problems] To provide a method for treating and/or preventing osteoporosis with teriparatide or a salt thereof, the method having excellent safety and/or efficacies. [Solving Means] A method for treating and/or preventing osteoporosis in which teriparatide or a salt thereof is an active ingredient, including administering teriparatide or a salt thereof in a unit dose of 28.2 ?g at a frequency of twice a week.Type: ApplicationFiled: November 25, 2020Publication date: March 18, 2021Applicant: ASAHI KASEI PHARMA CORPORATIONInventors: Takeshi MINAMIDA, Ryo KATO, Akira KOIKE, Atsushi OSE, Akihiro KITAMI, Takashi MAKIYAMA, Hikaru YAMAMOTO, Kazuhiko KITAGAWA, Ryoko TAKAO
-
Patent number: 10900063Abstract: An object of the present invention is to provide a highly versatile, simple and safe method for measuring Lp-PLA2 activity. Another object of the present invention is to provide an accurate and highly sensitive method for measuring Lp-PLA2 activity. Provided is a method for measuring lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in a sample containing Lp-PLA2, the method comprising the following steps (A) to (C): (A) converting PAFs into lyso-PAFs by reacting the PAFs with the Lp-PLA2 in the sample; (B) hydrolyzing the lyso-PAFs produced in the step (A) with an enzyme (lyso-PAF-PLD) to obtain hydrolysate; and (C) measuring Lp-PLA2 activity in the sample by utilizing a quantitative change attributable to the hydrolysate obtained in step (B) as an indicator.Type: GrantFiled: June 15, 2017Date of Patent: January 26, 2021Assignee: ASAHI KASEI PHARMA CORPORATIONInventors: Shinichi Sakasegawa, Saki Yamaura, Daisuke Sugimori
-
Publication number: 20200405706Abstract: The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the P2X7 receptor.Type: ApplicationFiled: March 13, 2018Publication date: December 31, 2020Applicants: RaQualia Pharma Inc., Asahi Kasei Pharma CorporationInventors: Hirohide NOGUCHI, Yoshimasa ARANO, Kazuo ANDO, Kazuki TOYOSHIMA, Toshihiko SONE, Koki MATSUBARA
-
Publication number: 20200347046Abstract: A novel compound represented by the following general formula (1), or a salt thereof, which has a superior EP4 receptor agonist activity, and a medicament containing the compound or a salt thereof as an active ingredient, which can be used for promotion of osteogenesis, therapeutic treatment and/or promotion of healing of fracture and the like.Type: ApplicationFiled: December 25, 2018Publication date: November 5, 2020Applicant: Asahi Kasei Pharma CorporationInventors: Daisuke SHIKANAI, Noriko ISHIGURO, Osamu OMORI
-
Publication number: 20200289621Abstract: According to the present invention, a liquid pharmaceutical preparation containing teriparatide or a salt thereof having excellent physical properties, the liquid pharmaceutical preparation containing teriparatide or a salt thereof, and at least one or more members of inorganic salts and/or organic salts is provided.Type: ApplicationFiled: September 20, 2018Publication date: September 17, 2020Applicant: ASAHI KASEI PHARMA CORPORATIONInventors: Kohei MIYABE, Takahiro YAMAGUCHI, Yasuhiro MATSUNAWA, Narumi WATANABE
-
Publication number: 20200289622Abstract: A liquid pharmaceutical preparation for subcutaneous administration in human containing 28.2 ?g of teriparatide or a salt thereof (Component 1) in a unit dose in terms of teriparatide, wherein the Component 1 concentration is from 80 to 240 ?g/mL. This liquid pharmaceutical preparation is excellent in the viewpoint of pharmacokinetics.Type: ApplicationFiled: September 20, 2018Publication date: September 17, 2020Applicant: ASAHI KASEI PHARMA CORPORATIONInventors: Kohei MIYABE, Atsushi OSE, Yuki SATO, Toshiyuki KODAMA, Yasuhiro MATSUNAWA, Hikaru YAMAMOTO
-
Patent number: 10709767Abstract: A medicament effective for prophylactic and/or therapeutic treatment of a peripheral neuropathic pain such as allodynia caused by a treatment with an anticancer agent, which comprises thrombomodulin as an active ingredient.Type: GrantFiled: May 17, 2013Date of Patent: July 14, 2020Assignees: KINKI UNIVERSITY, ASAHI KASEI PHARMA CORPORATIONInventors: Atsufumi Kawabata, Hideaki Suzuki
-
Patent number: 10683335Abstract: Provided herein are freeze-dried preparations comprising a high-purity parathyroid hormone (PTH) peptide and one or more PTH analogs, and methods for the production thereof. Also provided is a test method for detecting PTH analogs to confirm the purity of a freeze-dried preparation containing PTH peptide, and the like.Type: GrantFiled: May 29, 2018Date of Patent: June 16, 2020Assignee: ASAHI KASEI PHARMA CORPORATIONInventors: Fumihide Nishio, Takuji Maejima, Yoshiro Mitome
-
Publication number: 20200101139Abstract: An object of the present invention is to provide an effective and safe medicament having effects for mitigating conditions and/or suppressing onset of a peripheral neuropathy induced by administration of an anti-malignant tumor agent, oxaliplatin, in a human cancer patient receiving an anti-malignant tumor treatment with oxaliplatin. There is provided a medicament for mitigating conditions and/or suppressing onset of a peripheral neuropathy induced by oxaliplatin in an anti-malignant tumor treatment consisting of repetition of a single cycle comprising intravenous administration of oxaliplatin to a human cancer patient and following drug withdrawal, which contains thrombomodulin for intravenously administering 0.06 mg/kg of thrombomodulin once per said single cycle of the treatment on the first day of each said cycle as an active ingredient.Type: ApplicationFiled: October 18, 2019Publication date: April 2, 2020Applicant: Asahi Kasei Pharma CorporationInventors: Takumi SAKAI, Genichi KUSAKAWA, Yugo UCHIDA
-
Patent number: 10588945Abstract: [Problem] To provide an agent for preventing the onset of idiopathic osteonecrosis of the femoral head and/or suppressing the progress of the same. [Solution] An agent for preventing the onset of idiopathic osteonecrosis of the femoral head and/or suppressing the progress of the same comprising parathyroid hormone or a derivative thereof as an active ingredient, characterized by being administered intermittently.Type: GrantFiled: July 4, 2016Date of Patent: March 17, 2020Assignees: ASAHI KASEI PHARMA CORPORATION, NATIONAL UNIVERSITY CORPORATION ASAHIKAWA MEDICAL UNIVERSITYInventors: Hiromasa Tanino, Hiroshi Ito
-
Publication number: 20200002744Abstract: An object of the present invention is to provide a highly versatile, simple and safe method for measuring Lp-PLA2 activity. Another object of the present invention is to provide an accurate and highly sensitive method for measuring Lp-PLA2 activity. Provided is a method for measuring lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in a sample containing Lp-PLA2, the method comprising the following steps (A) to (C): (A) converting PAFs into lyso-PAFs by reacting the PAFs with the Lp-PLA2 in the sample; (B) hydrolyzing the lyso-PAFs produced in the step (A) with an enzyme (lyso-PAF-PLD) to obtain hydrolysate; and (C) measuring Lp-PLA2 activity in the sample by utilizing a quantitative change attributable to the hydrolysate obtained in step (B) as an indicator.Type: ApplicationFiled: June 15, 2017Publication date: January 2, 2020Applicant: ASAHI KASEI PHARMA CORPORATIONInventors: Shinichi SAKASEGAWA, Saki YAMAURA, Daisuke SUGIMORI
-
Patent number: 10472665Abstract: The present invention provides a measuring method for at least one of a kinase forward reaction substrate, a phosphorylated product thereof, and a precursor thereof, and includes a step of conducting an enzymatic cycling reaction by bringing at least a kinase, a first nucleotide coenzyme of the kinase, and a second nucleotide coenzyme having a different nucleoside moiety from the first nucleotide coenzyme into contact with a sample; a step of detecting a signal corresponding to a change of at least one of the first nucleotide coenzyme and a conversion product thereof, and the second nucleotide coenzyme and a conversion product thereof; and (3) a step of calculating, on the basis of the detected change of the signal, an amount of the kinase forward reaction substrate and/or the phosphorylated product thereof contained in the sample.Type: GrantFiled: September 18, 2015Date of Patent: November 12, 2019Assignee: ASAHI KASEI PHARMA CORPORATIONInventors: Shigeru Ueda, Shinichi Sakasegawa
-
Publication number: 20190170762Abstract: An object of the present invention is to provide a method of measuring a glycated-albumin (GA) value traceable to a certified GA value conveniently at a low cost in a short period of time. A method of measuring a GA value traceable to the certified GA value includes the following steps: A1) determining Regression equation III by steps including the following b), c), and e0) to h); b) determining a GA concentration [L] (A) of two or more GA certified reference materials having respectively different certified GA values; c) measuring a GA-derived absorbance (D) of the two or more GA certified reference materials; e0) creating Linear equation II0 having an intercept of zero; f) determining two or more GA concentrations[P] (E) proportionate to the GA-derived absorbance (D) according to Equation II0; g) determining two or more GA values (F); and h) creating Regression equation III.Type: ApplicationFiled: July 19, 2017Publication date: June 6, 2019Applicant: ASAHI KASEI PHARMA CORPORATIONInventor: Ryosuke KOGUMA
-
Publication number: 20180185454Abstract: [Problem] To provide an agent for preventing the onset of idiopathic osteonecrosis of the femoral head and/or suppressing the progress of the same. [Solution] An agent for preventing the onset of idiopathic osteonecrosis of the femoral head and/or suppressing the progress of the same comprising parathyroid hormone or a derivative thereof as an active ingredient, characterized by being administered intermittently.Type: ApplicationFiled: July 4, 2016Publication date: July 5, 2018Applicants: ASAHI KASEI PHARMA CORPORATION, NATIONAL UNIVERSITY CORPORATION ASAHIKAWA MEDICAL UNIVERSITYInventors: Hiromasa TANINO, Hiroshi ITO
-
Patent number: 10011643Abstract: [Problem] Provided is a freeze-dried preparation containing high-purity PTH peptide and a method for the production thereof. Also provided is a test method for PTH analogs to confirm the purity of a freeze-dried preparation containing PTH peptide, and the like. [Solution] In the present invention, the presence of PTH analogs produced during the manufacturing process of a freeze-dried preparation containing PTH peptide was confirmed. The production of these PTH analogs was also discovered to be markedly prevented or reduced by controlling exposure of the solution containing PTH peptide and the like to air environments within a pharmaceutical production facility.Type: GrantFiled: January 8, 2016Date of Patent: July 3, 2018Assignee: ASAHI KASEI PHARMA CORPORATIONInventors: Fumihide Nishio, Takuji Maejima, Yoshiro Mitome
-
Patent number: 10000791Abstract: A measurement method for human pancreatic lipase activity in a sample, includes bringing a bile acid that makes a pH for giving a maximum value of human pancreatic lipase activity to be lower than 7.7, a diglyceride and a colipase into contact with the sample at pH 7.4 or lower; and detecting a signal amount varying in accordance with the human pancreatic lipase activity in the sample, and the bile acid is a bile acid containing: one of or two or more of a-type bile acids selected from the group consisting of GDCA, GCDCA, TDCA, TCDCA and salts thereof; and/or a combination of one of or two or more of b-1-type bile acids selected from the group consisting of GCA, GUDCA, TCA, TUDCA and salts thereof, and one of or two or more of b-2-type bile acids selected from the group consisting of DCA, CDCA and salts thereof.Type: GrantFiled: April 17, 2014Date of Patent: June 19, 2018Assignee: ASAHI KASEI PHARMA CORPORATIONInventors: Shigeru Ueda, Shinichi Sakasegawa
-
Publication number: 20170306389Abstract: The present invention provides a measuring method for at least one of a kinase forward reaction substrate, a phosphorylated product thereof, and a precursor thereof, and includes a step of conducting an enzymatic cycling reaction by bringing at least a kinase, a first nucleotide coenzyme of the kinase, and a second nucleotide coenzyme having a different nucleoside moiety from the first nucleotide coenzyme into contact with a sample; a step of detecting a signal corresponding to a change of at least one of the first nucleotide coenzyme and a conversion product thereof, and the second nucleotide coenzyme and a conversion product thereof; and (3) a step of calculating, on the basis of the detected change of the signal, an amount of the kinase forward reaction substrate and/or the phosphorylated product thereof contained in the sample.Type: ApplicationFiled: September 18, 2015Publication date: October 26, 2017Applicant: ASAHI KASEI PHARMA CORPORATIONInventors: Shigeru UEDA, Shinichi SAKASEGAWA
-
Patent number: 9790492Abstract: [Problem] To provide the following: an agent for treating cancer, particularly an agent for inhibiting cancer cell proliferation or an agent for inhibiting or preventing cancer metastasis; drug that uses the agent; a method for assessing the effect of cancer treatment; a method for estimating the prognosis of cancer treatment; a method for screening for a substance having a cancer proliferation-inhibiting effect; and a method for screening a substance having a cancer metastasis-impeding effect. [Solution] Provided is a drug containing a nucleic acid formed from a nucleotide sequence having sequence identity of 70% or greater with at least sequence No. 1 or No. 2, wherein the nucleic acid shows protein expression-inhibiting activity.Type: GrantFiled: August 19, 2013Date of Patent: October 17, 2017Assignees: NATIONAL CANCER CENTER, ASAHI KASEI PHARMA CORPORATIONInventors: Takahiro Ochiya, Fumitaka Takeshita
-
Patent number: 9592275Abstract: A medicament for therapeutic treatment and/or improvement of sepsis in a patient with severe sepsis accompanied with one or more organ dysfunctions, wherein a value of International Normalized Ratio (INR) of a plasma specimen obtained from said patient is more than 1.4, which comprises thrombomodulin as an active ingredient.Type: GrantFiled: November 14, 2012Date of Patent: March 14, 2017Assignee: ASAHI KASEI PHARMA CORPORATIONInventors: Kazuhisa Tsuruta, Yoshikazu Aoki, Yutaka Osawa, Inder Kaul
-
Publication number: 20170037443Abstract: The present invention provides a method for measuring the concentration of an analyte in a test solution wherein the analyte is mevalonic acid and/or 3-hydroxymethylglutaryl coenzyme A, comprising the following steps (p) and (q): (p) a step of allowing an enzyme that catalyzes a reaction represented by Reaction Formula 1 and an enzyme that catalyzes a reaction represented by Reaction Formula 2 to act on a test solution containing mevalonic acid and/or 3-hydroxymethylglutaryl coenzyme A in the presence of a hydrogen acceptor X, a hydrogen donor Y, and coenzyme A; and (q) a step of measuring an amount of: a reduced hydrogen acceptor X that is produced; or an oxidized hydrogen donor Y that is produced; or a hydrogen acceptor X that is decreased; or a hydrogen donor Y that is decreased, wherein the hydrogen donor Y and the reduced hydrogen acceptor X are not the same.Type: ApplicationFiled: August 11, 2016Publication date: February 9, 2017Applicant: ASAHI KASEI PHARMA CORPORATIONInventor: Takeshi MATSUOKA